| Identification | Back Directory | [Name]
Pregna-1,4-diene-3,20-dione, 16,17-[[(R)-[4-[(3-aminophenyl)methyl]phenyl]methylene]bis(oxy)]-11,21-dihydroxy-, (11β,16α)- | [CAS]
2166375-82-0 | [Synonyms]
Glucocorticoid receptor agonist-1
Pregna-1,4-diene-3,20-dione, 16,17-[[(R)-[4-[(3-aminophenyl)methyl]phenyl]methylene]bis(oxy)]-11,21-dihydroxy-, (11β,16α)- | [Molecular Formula]
C35H39NO6 | [MOL File]
2166375-82-0.mol | [Molecular Weight]
569.7 |
| Chemical Properties | Back Directory | [Boiling point ]
778.5±60.0 °C(Predicted) | [density ]
1.34±0.1 g/cm3(Predicted) | [storage temp. ]
4°C, protect from light | [form ]
Solid | [pka]
12.87±0.10(Predicted) | [color ]
White to off-white |
| Hazard Information | Back Directory | [Biological Activity]
Glucocorticoid receptor agonist-1 is a potent glucocorticoid receptor agonist with an IC50 of 2.8 nM extracted from patent WO2017210471A1, compound 41[1].
Glucocorticoid receptor agonist immunoconjugates are useful for treating autoimmune diseases such as, but not limited to, rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, adult Crohn’s disease, pediatric Crohn’s disease, ulcerative colitis, plaque psoriasis, hidradenitis suppurativa, uveitis, Behcets disease, a spondyloarthropathy, or psoriasis[1]. | [storage]
4°C, protect from light | [References]
[1]. Michael J. Mcpherson, et al. Glucocorticoid receptor agonist and immunoconjugates thereof. WO2017210471A1. |
|
|